Corrective Phases R...
Health Care: Drugs
Agenus Inc. (AGEN: NASDAQ)
$2.48 0.06 | 2.48%
12/01/11 - 04:00 PM ET
Company Cash Flow
| Dec 2011 | Dec 2010 | Dec 2009 | Dec 2008 | |
| Cash Flow From Operating Activities | ||||
|---|---|---|---|---|
| Net Income (Loss) | -23.28M | -21.91M | -30.32M | -28.70M |
| Operating Gains/Losses | 37.45K | -2.60M | -2.28M | -13.24M |
| Extraordinary Gains / Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| (Increase) Decrease In Receivables | 35.00K | -35.00K | 0.00 | 318.71K |
| (Increase) Decrease in Inventories | 6.36K | 297.60K | -97.66K | 284.50K |
| (Increase) Decrease In Other Current Assets | 0.00 | 0.00 | 0.00 | 0.00 |
| (Decrease) Increase In Payables | 105.67K | -198.12K | 296.09K | -133.94K |
| (Decrease) Increase In Other Current Liabilities | -269.71K | -246.88K | -2.12M | -690.73K |
| (Increase) Decrease In Other Working Capital | -2.12M | 521.88K | -733.96K | 530.70K |
| Other Non-Cash Items | 6.81M | 5.92M | 7.10M | 7.82M |
| Net Cash From Continuing Operations | -16.25M | -14.76M | -24.19M | -28.91M |
| Net Cash From Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Provided By Investing Activities | ||||
| Net Cash From Total Operating Activities | -16.25M | -14.76M | -24.19M | -28.91M |
| Sale of Property, Plant & Equipment | 23.88K | 50.30K | 53.55K | 2.00M |
| Cash Used for Investing Activities | ||||
| Sale of Short-Term Investments | 5.00M | 40.00M | 30.00M | 24.12M |
| Purchases of Property, Plant & Equipment | -54.55K | -130.44K | -243.87K | -206.01K |
| Acquisitions | 0.00 | 0.00 | 0.00 | 0.00 |
| Purchases of Short-Term Investments | -5.00M | -29.99M | -29.99M | -29.91M |
| Other Cash from Investing Activities | 0.00 | 0.00 | 2.34M | 0.00 |
| Cash Provided by Financing Activities | ||||
| Net Cash From Investing Activities | -29.46K | 9.93M | 2.16M | -4.00M |
| Issuance of Debt | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Used for Financing Activities | ||||
| Issuance of Capital Stock | 8.06M | 11.57M | 18.73M | 333.49K |
| Repayment of Long-Term Debt | -28.06K | -6.24M | -255.00K | -2.93M |
| Repurchase of Capital Stock | 0.00 | 0.00 | -54.94K | -257.68K |
| Payment of Cash Dividends | -790.50K | -790.50K | -790.50K | -790.50K |
| Other Financing Charges, Net | 0.00 | 0.00 | 0.00 | 46.55M |
| Net Cash From Financing Activities | 7.24M | 4.54M | 17.63M | 42.90M |
| Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Change in Cash & Cash Equivalents | -9.03M | -284.84K | -4.40M | 9.99M |
Portfolios with AGEN
- Portfolio NameUser Type
- UserKJP Save Stockpickr Fund
- ContributorStocks Under-$10 Moving Hig...
- ProRobert Bruce
- Contributor16 Small-Cap Stocks in Dang...
- UserASCO 2010
- Userhp22puch Portfolio 1
- Usernvoelz Portfolio 1
- UserPix's Stocks
- UserArsenD Portfolio 1
- UserMikejo10 Portfolio 1
Latest AGEN Headlines from TheStreet
- Biotech Stock Mailbag: All You Need to Know About Hep C Drugs 04.13.12 | 05:04 am
- 3 Stocks Under $10 Moving Higher 03.29.12 | 12:03 pm
- Agenus' CEO Discusses Q4 2011 Results - Earnings Call Transcript 03.05.12 | 03:03 pm
- Agenus Only Gets A Mosquito-Sized Bite of the New And Heralded Malaria Vaccine 10.18.11 | 03:10 pm
- Agenus Stock Gaps Down On Today's Open (AGEN) 10.07.11 | 09:10 am
- Agenus' CEO Discusses Q2 2011 Results - Earnings Call Transcript 07.29.11 | 10:07 pm
- Oncothyreon: Deep Dive Into Stimuvax 07.11.11 | 07:07 am
- Biotech Data Mining Comes Up Empty 06.29.11 | 07:06 am
- ASCO: Cancer Stock Winners, Losers 05.19.11 | 10:05 am
- Agenus Receives NASDAQ Delisting Notification 03.04.11 | 09:03 am
Press Releases for AGEN
- The Fourth Product Candidate Containing Antigenics' QS-21 In Phase 3 Clinical Development - Business Wire 08.25.10 | 02:08 pm
- Antigenics Reports Second Quarter 2010 Financial Results - Business Wire 07.29.10 | 07:07 am
- Antigenics Presents Positive, Top Line Data From Phase I Herpes Clinical Trial - Business Wire 07.27.10 | 07:07 am
- Antigenics To Report Second Quarter Financial Results On July 29, 2010; Conference Call To Follow - Business Wire 07.22.10 | 07:07 am
- Antigenics Receives NASDAQ Delisting Notification - Business Wire 07.21.10 | 04:07 pm
- Encouraging Data Presented On Oncophage® Vaccine At International Conference On Brain Tumor Research And Therapy - Business Wire 05.20.10 | 07:05 am
- Antigenics To Webcast 2010 Annual Shareholders Meeting - Business Wire 04.29.10 | 07:04 am
- Antigenics Reports First Quarter 2010 Financial Results - Business Wire 04.29.10 | 07:04 am
- Antigenics To Report First Quarter Financial Results On April 29, 2010; Conference Call To Follow - Business Wire 04.22.10 | 07:04 am
- Antigenics To Report Fourth Quarter And Year-End 2009 Financial Results On February 18, 2010; Conference Call To Follow - Business Wire 02.11.10 | 07:02 am
Partner Headlines for AGEN
- Zacks #1 Rank Additions for Thursday - Tale of the Tape - Zacks 05.17.12 | 09:05 am
- Zacks #1 Rank Additions for Monday - Tale of the Tape - Zacks 05.14.12 | 09:05 am
- Stocks To Watch: Week Of March 19-23 - Seeking Alpha 03.21.12 | 08:03 am
- Market Update - Benzinga 03.20.12 | 09:03 am
- Agenus Continues to Outperform - Seeking Alpha 03.16.12 | 06:03 pm
- 7 Biotech Stocks Being Snapped Up By Insiders - Seeking Alpha 03.16.12 | 05:03 pm
- Agenus Still Gaining On GSK Agreement Expansion - Seeking Alpha 03.15.12 | 08:03 am
- Insider Buys May Send The Wrong Signals - Seeking Alpha 08.22.11 | 09:08 am
- ASCO 2011: Opportunities for Biotech Investor Success and Failure - Seeking Alpha 05.02.11 | 09:05 am
- Antigenics changes name to Agenus - Reuters 01.06.11 | 01:01 pm
